Michael Lotze, M.D.
Lab: HLMNC G27.A
- M.D., Northwestern University
- Assistant Vice Chancellor for Sponsored Training Grants, Health Sciences
- Professor, Department of Surgery
- Professor, Department of Bioengineering
- Vice Chair, Surgery Research
- Director, Strategic Partnerships, University of Pittsburgh Cancer Institute
- Director, Catalyst Program, Clinical and Translational Science Institute
Farkas AM. Kilgore TM. Lotze MT. Detecting DNA: Getting and begetting cancer. Current Opinion in Investigational Drugs. 8(12):981-6, 2007.
Lotze MT. Zeh HJ. Rubartelli A. Sparvero LJ. Amoscato AA. Washburn NR. Devera ME. Liang X. Tor M. Billiar T. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunological Reviews. 220:60-81, 2007.
Lotze MT. Gray J. A life in passing: Jonathan Gray. Journal of Translational Medicine. 5:54, 2007.
Atkins, M.B., Carbone, D., Coukos, G., Dhodapkar, M., Ernstoff, M.S., Finke, J., Gajewski, T.F., Gollob, J., Lotze, M.T., Storkus, W., Weiner, L.M. Report on the iSBTc mini-symposium on biologic effects of targeted therapeutics. Journal of Immunotherapy 2007;30(6):577-590.
Dong Xda, E., Ito, N., Lotze, M.T., DeMarco, R.A., Popovic, P., Shand, S.H., Watkins, S., Winikoff, S., Brown, C.K., Bartlett, D.L., Zeh, H.J. 3rd. High mobility group box 1 (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. Journal of Immunotherapy 2007;30(6):596-606.
- NK and DC interactions in tumor immunity
- Imaging Cytometry
- Damage associated molecular pattern molecules including HMGB1 and its receptors, RAGE and TLR4
- Measures of DNA as a DAMP in cancer
- Redox regulation of immunity
Professor of Surgery, Immunology, and Bioengineering, University of Pittsburgh School of Medicine; Vice Chair of Research, Department of Surgery; Associate Director for Strategic Partnerships, University of Pittsburgh Cancer Institute; Asst. Vice Chancellor, UPSHS. Bachelor of Biomedical Sciences and MD, Northwestern University (Evanston, Chicago), 1973, 1974. Dr. Lotze's primary area of research is in tumor immunology, particularly the role of cellular therapy using dendritic cells and NK cells. His current research interests include the further identification of clinical biomarkers and surrogates in the setting of chronic inflammatory disease, the analysis and application of biomedical instrumentation including multicolor flow cytometry, high content imaging of intracellular signaling in response to cytokines, and the role of autophagy, the nuclear protein high molecular group B1 [HMGB1] and other Damage Associated Molecular Pattern Molecules [DAMPs] in tissue injury, repair, and cancer.